British biotech startup Broken String Biosciences raises €14M to develop, commercialise its INDUCE-seq tech

Broken String Biosciences is a genomics company that is building a technology platform to drive the development of cell & gene therapies that are safer by design.  Here are details of Broken String Biosciences’s latest funding round :

🚀 Launch


🏭 Industry



Felix Dobbs, Simon Reed, Simon Kerr, Vincent Smith, Jessica Rich, Patrick van Eijk, Anthony Underwood, Sam Huguet

💸 Funding & Investors

  • Investment (September 2023) : €14 million (Series A). In September 2021, it secured nearly $4M in a Series Seed round from investors across the UK, Germany, and the US.
  • Investors : co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners and participation from existing investors Tencent and Dieter von Holtzbrinck Ventures.

🎯 Funding purpose

Product development, growth and expansion in the US.

🌐 Country HQ

UK (Cambridge)

Leave a Reply

Your email address will not be published.